Taking responsibility: Asilomar and its legacy
By J. Benjamin Hurlbut,
Science
| 01. 30. 2025
In February 1975, leading molecular biologists gathered at the Asilomar conference center on the California coast to evaluate risks of the emerging technology of recombinant DNA and to establish guidelines to govern research. The meeting is remembered as a defining moment in the making of molecular biology. Yet its legacy lies not in specific rules it developed but in the approach to scientific self-regulation that it crystallized. Five decades later, this near-mythic “meeting that changed the world” is held up as a precedent to celebrate and a model to emulate: Scientists take responsibility for governing themselves, solidifying public trust while securing future benefits of technology for society. But although this may elicit public acquiescence and secure scientific autonomy in the short run, ultimately it has engendered reactive distrust. The 50th anniversary affords a moment for taking stock of Asilomar’s legacy and its implications for science and democracy. Its lessons are difficult.
The Asilomar meeting is held up as an exemplar of how scientists can navigate between the Scylla of technological risk and the Charybdis of public reaction and overregulation (...
Related Articles
By Mike McIntire, The New York Times | 01.24.2026
Genetic researchers were seeking children for an ambitious, federally funded project to track brain development — a study that they told families could yield invaluable discoveries about DNA’s impact on behavior and disease.
They also promised that the children’s sensitive...
By Arthur Lazarus, MedPage Today | 01.23.2026
A growing body of contemporary research and reporting exposes how old ideas can find new life when repurposed within modern systems of medicine, technology, and public policy. Over the last decade, several trends have converged:
- The rise of polygenic scoring...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...